At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 22 enrolled
Drug / intervention
Pramlintidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
In Brief
A Phase 4 clinical trial evaluating Pramlintide for Hypoglycemia and Evidence of Previous Gastric Surgery. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether pramlintide (Symlin) will help to reduce the frequency and severity of hypoglycemia in individuals who have had gastric bypass surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoglycemia, Evidence of Previous Gastric Surgery
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedApr 2013
Primary CompletionJul 2016
Study CompletionFeb 2022
TodayJul 2026
First PostedApr 26, 2013
Enrollment StartFeb 2, 2010
Primary CompletionJul 1, 2016
Study CompletionFeb 8, 2022
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 13.2 years ago
Interventions
Pramlintidedrug
See description above (arm description).